Hyderabad: Hyderabad-based Hetero unveiled results of phase III trials of Movfor (Molnupiravir), an investigational oral antiviral Covid-19 drug. The company demonstrated that Molnupiravir along with Standard of Care (SOC) reduced the risk of hospitalisation by over 65 per cent compared to SOC alone. The results were presented as an oral abstract at the Conference on […]
